Stifel, a major investment firm, just bumped up its price target for Soleno Therapeutics' stock to $115, signaling strong confidence in the company. The boost comes as demand for Vykat, one of Soleno's key drugs, looks promising. Investors are clearly betting on growth here.

Editor’s Note: When analysts raise price targets like this, it’s usually a big vote of confidence—especially in the volatile biotech sector. If Vykat’s demand stays strong, Soleno could be in for a solid run. For anyone tracking pharma stocks or growth opportunities, this is worth keeping an eye on.